Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids

被引:96
作者
Bruna, A
Nicolàs, M
Muñoz, A
Kyriakis, JM
Caelles, C [1 ]
机构
[1] Univ Barcelona, IRBB PCB, E-08028 Barcelona, Spain
[2] Univ Barcelona, Dept Bioquim & Biol Mol, Div 4, E-08028 Barcelona, Spain
[3] Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain
[4] Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA
关键词
AP-1; antagonism; cell signaling; cross-talk; MAPK docking site; MAPK pathway;
D O I
10.1093/emboj/cdg590
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Inhibition of the c-Jun N-terminal kinase (JNK) pathway by glucocorticoids (GCs) results in AP-1 repression. GC antagonism of AP-1 relies mainly on the transrepression function of the GC receptor (GR) and mediates essential physiological and pharmacological actions. Here we show that GCs induce the disassembly of JNK from mitogen-activated protein kinase kinase 7 (MKK7) by promoting its association with GR. Moreover, we have characterized a hormone-regulated JNK docking site in the GR ligand-binding domain that mediates GR-JNK interaction. The binding of GR to JNK is required for inhibition of JNK activation and induction of inactive JNK nuclear transfer by GCs. The dissociation of these two hormone actions shows that JNK nuclear transfer is dispensable for the downregulation of JNK activation by GCs. Nonetheless, nuclear accumulation of inactive JNK may still be relevant for enhancing the repression of AP-1 activity by GCs. In this regard, chromatin immunoprecipitation assays show that GC-induced GR-JNK association correlates with an increase in the loading of inactive JNK on the AP-1-bound response elements of the c-jun gene.
引用
收藏
页码:6035 / 6044
页数:10
相关论文
共 41 条
  • [1] THE JUN PROTO-ONCOGENE IS POSITIVELY AUTOREGULATED BY ITS PRODUCT, JUN/AP-1
    ANGEL, P
    HATTORI, K
    SMEAL, T
    KARIN, M
    [J]. CELL, 1988, 55 (05) : 875 - 885
  • [2] Anti-inflammatory actions of glucocorticoids: molecular mechanisms
    Barnes, PJ
    [J]. CLINICAL SCIENCE, 1998, 94 (06) : 557 - 572
  • [3] Identification of the critical features of a small peptide inhibitor of JNK activity
    Barr, RK
    Kendrick, TS
    Bogoyevitch, MA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (13) : 10987 - 10997
  • [4] STEROID-HORMONE RECEPTORS - MANY ACTORS IN SEARCH OF A PLOT
    BEATO, M
    HERRLICH, P
    SCHUTZ, G
    [J]. CELL, 1995, 83 (06) : 851 - 857
  • [5] Cell-permeable peptide inhibitors of JNK novel blockers of β-cell death
    Bonny, C
    Oberson, A
    Negri, S
    Sauser, C
    Schorderet, DF
    [J]. DIABETES, 2001, 50 (01) : 77 - 82
  • [6] Caelles C, 2002, E SCHERING RES FDN W, V40, P131
  • [7] Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway
    Caelles, C
    González-Sancho, JM
    Muñoz, A
    [J]. GENES & DEVELOPMENT, 1997, 11 (24) : 3351 - 3364
  • [8] Direct activation of mitogen-activated protein kinase kinase kinase MEKK1 by the Ste20p homologue GCK and the adapter protein TRAF2
    Chadee, DN
    Yuasa, T
    Kyriakis, JM
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (03) : 737 - 749
  • [9] TARGETED DISRUPTION OF THE GLUCOCORTICOID RECEPTOR GENE BLOCKS ADRENERGIC CHROMAFFIN CELL-DEVELOPMENT AND SEVERELY RETARDS LUNG MATURATION
    COLE, TJ
    BLENDY, JA
    MONAGHAN, AP
    KRIEGLSTEIN, K
    SCHMID, W
    AGUZZI, A
    FANTUZZI, G
    HUMMLER, E
    UNSICKER, K
    SCHUTZ, G
    [J]. GENES & DEVELOPMENT, 1995, 9 (13) : 1608 - 1621
  • [10] DAI TN, 1995, ONCOGENE, V10, P849